Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065060 · ClinicalTrials.gov registry record
Parkinson Progression Marker Initiative Online (PPMI Online)
A clinical trial of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Recruiting
- Registry status
- 500,000
- Enrollment target
- 1
- Study location
NCT05065060: Recruiting study of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
NCT05065060 is a study of Parkinson Disease that is actively recruiting participants, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 500,000 participants, above the 3,643-participant average among 297 other Parkinson Disease trials with a reported enrollment target (13625% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05065060, a study of Parkinson Disease, is actively recruiting participants, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- RECRUITING
- Registry status
- 500,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD. PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Primary Outcome
Evaluates self-reported motor and nonmotor Parkinson's disease symptoms
Conditions Studied
Interventions
- OTHER Observation
Study Locations (1)
California
- UCSF Movement Disorders and Neuromodulation Center (MDNC) - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500,000 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2041-12 |
What NCT05065060 shows while recruiting
NCT05065060 is an observational study that tracks outcomes without assigning an intervention. Its 500,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,643-participant average among 297 other Parkinson Disease trials with a reported enrollment target (13625% higher).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT05065060 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05065060 about?
NCT05065060 is a clinical study titled "Parkinson Progression Marker Initiative Online (PPMI Online)". Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD. PPMI Online is part of the broader Parki...
What is the current status of trial NCT05065060?
This trial is currently recruiting. The enrollment target is 500,000 participants. The study started on 2021-07-28. Estimated completion is 2041-12.
What conditions does trial NCT05065060 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT05065060?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT05065060?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05065060 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05065060's enrollment target sits among peer trials
500,000 2nd of 297 the highest of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
- NCT06342375 · 425,000 participants · NA
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
- NCT06934239 · 400,000 participants · Phase 4
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
- NCT05668637 · 318,542 participants
Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI